However, we did observe an increase in the expression of PD-1 on the CD8+ TIL and significantly increased mRNA expression of Pd-l1 in the tumor tissues from the Lm-LLO-CD105A treated mice (Supplementary Figures S4E, F), suggesting that the combination of Lm-LLO-CD105A with anti-PD-1/PD-L1 therapy may provide synergistic therapeutic efficacy. Here, CD8A is linked to neoplasm.